Identifying and adapting treatment for frailty in cardiovascular disease

“The quality of what Pharmacy Management is putting on is simply streets ahead of anything else I’m seeing at the moment. Keep up the good work!”
Noel Wicks, Managing Director, Right Medicine Pharmacy Ltd, Stirling
Satellite Identifying and adapting treatment for frailty in cardiovascular disease
Speakers Paresh Parmar (Lead Stroke and Care of the Elderly Pharmacist, London North West Healthcare NHS Trust)
Satellite Description

People are living longer, but not necessarily ageing healthier.  Frailty is an important prognostic factor in patients with CVD, and so identifying this feature when assessing these patients may help to individually tailor cardiovascular treatment. Frailty and polypharmacy pose challenges in managing these patients with multiple co-morbidities including cardiovascular disease and their medication. Inappropriate polypharmacy places patients at higher risk of adverse effects and unplanned hospital visits. Understanding what frailty is and how polypharmacy affects frail patients with cardiovascular disease will lead to better medication management through person centred care. .

Foundation level.

Back to Course

Connect with us Industry NHS


This site is intended for healthcare professionals or people employed in the pharmaceutical industry. Please confirm that you are such a person.